SignalXSignalX

GILD Gilead Sciences

FY2024 10-K
Filed: Feb 28, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR
Gilead Sciences Overview

Gilead Sciences (GILD) filed its fiscal year 2024 10-K annual report with the SEC on Feb 28, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2024 10-K

Business Overview

  • • Core biopharmaceutical model focused on innovative medicines for life-threatening diseases including HIV, viral hepatitis, COVID-19, cancer, inflammation
  • • Continued emphasis on fixed-dose combination oral HIV therapies like Biktarvy, Genvoya, Descovy, with FDA-approved PrEP indication for Descovy highlighted this year
+3 more insights

Management Discussion & Analysis

  • • Revenue $28.8B, up 6% YoY from $27.1B, driven by HIV, Oncology, Liver Disease sales; Veklury sales declined
  • • Net income $480M, down 92% YoY from $5.7B; impacted by $4.2B IPR&D impairment and $3.8B CymaBay acquisition expenses
+3 more insights

Risk Factors

  • • FDA regulatory risk from ongoing antitrust probe involving HIV drug price practices by U.S. Federal Trade Commission
  • • U.S. market exposure with 70% of total product sales $20.5B concentrated in HIV products, sensitive to U.S. healthcare policy changes
+3 more insights

Financial Summary
XBRL

Revenue

$28.8B

Net Income

$480M

Operating Margin

5.8%

Net Margin

1.7%

ROE

2.5%

Total Assets

$59.0B

EPS (Diluted)

$0.38

Operating Cash Flow

$10.8B

Source: XBRL data from Gilead Sciences FY2024 10-K filing on SEC EDGAR. All figures in USD.

Other Gilead Sciences Annual Reports

FY2025 10-K

Get deeper insights on Gilead Sciences

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available